- Investing.com
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Metrics to compare | BIAF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIAFPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | −2.6x | −0.5x | |
PEG Ratio | −0.04 | −0.08 | 0.00 | |
Price/Book | 5.6x | 5.8x | 2.6x | |
Price / LTM Sales | 0.9x | 5.0x | 3.2x | |
Upside (Analyst Target) | - | 795.5% | 43.8% | |
Fair Value Upside | Unlock | 26.7% | 8.1% | Unlock |